



March 28, 2024

**MPOX vaccine update: Commercialization of JYNNEOS vaccine**

Dear colleagues,

Bavarian Nordic, the manufacturer of JYNNEOS vaccine which has been used to protect against mpox since the outbreak of 2022, has notified the United States Department of Health and Human Services of plans to make the vaccine available on the commercial market beginning in April. The New York State Department of Health, in conjunction with our federal partners, is committed to ensuring the continued availability and accessibility of JYNNEOS vaccine for all individuals who may be at risk of mpox exposure, including individuals who are uninsured or underinsured.

Currently, JYNNEOS vaccine is requested through the New York State Department of Health and the New York City Department of Health and Mental Hygiene from the federal Strategic National Stockpile. As JYNNEOS becomes commercially available, the federal government will wind down ordering and distribution of the Strategic National Stockpile's supply of JYNNEOS. It is expected that this transition will begin on April 30, 2024.

Consistent with the ordering and distribution process for other vaccines, JYNNEOS vaccine will be made available through Vaccines for Children (VFC) Program (for eligible adolescents) and Vaccines for Adults (VFA) Programs, likely within a few months of commercialization. Orders of vaccine from the Strategic National Stockpile placed through New York State Department of Health via [mpox@health.ny.gov](mailto:mpox@health.ny.gov) will be accepted only in cases where commercially available JYNNEOS is not available or accessible. Orders from this supply are expected to close in August 2024.

More information about the transition of JYNNEOS vaccine to the commercial market will be shared once it is available. Questions in the meantime can be sent to the New York State Department of Health via [mpox@health.ny.gov](mailto:mpox@health.ny.gov).